Clinical Trial Update: Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CKD-501 added to D150 Plus D745 25mg therapy for type 2 diabetes; efficacy and safety data not provided in snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CKD-501

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Type2 Diabetes | Phase 3 | Status: UNKNOWN